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Purpose: The primary aim of the present study was to assess the pharmacokinetic bioequiva-
lence between a generic formulation of meloxicam 15 mg tablets (Meloxicam Hexal) and its 
respective brand product (Mobic), in order to verify whether the generic product conforms to the 
regulatory standards of bioequivalence in the postmarketing setting. As a secondary exploratory 
aim, the pharmacodynamic effects of the two formulations were also evaluated by means of 
rating scales following hyperalgesia induced by cutaneous freeze injury.
Subjects and methods: A single 15 mg dose of generic or branded meloxicam tablets was 
administered to 24 healthy male volunteers in a crossover fashion. Plasma samples, collected 
for 24 hours after dosing, were assayed for meloxicam concentration by a validated high-
performance liquid chromatography method.
Results: The analysis of pharmacokinetic parameters did not show any significant difference 
between the two meloxicam formulations: the 90% confidence intervals fell within the accep-
tance range of 80%–125% (0.84–1.16 for area under the curve [0–24], and 0.89–1.23 for peak 
concentration). No difference in the pharmacodynamic end point was observed between the 
two groups.
Conclusion: The pharmacokinetic profiles of the two meloxicam formulations confirm the 
regulatory criteria for bioequivalence; pharmacodynamic data indicate a similar antihyperalgesic 
effect. The two formulations can be used interchangeably in the clinical setting.
Keywords: meloxicam, pharmacokinetics, healthy volunteers, generic drug, bioequivalence, 
postmarketing
Introduction
The purpose of assessing bioequivalence is to demonstrate equivalence in biophar-
maceutic quality between the generic medicinal product and the reference branded 
formulation, in order to allow bridging of preclinical tests and clinical trials associated 
with the patented original product. Accordingly, pharmaceutical companies, involved in 
the development of generic drugs, are allowed to follow abbreviated procedures to 
demonstrate bioequivalence between brand and generic formulations, without the 
need of repeating a complete, and expensive program of pharmacological and clinical 
development.1
In the Italian setting, open access to preregistration documentation of generic 
drugs is not allowed, and, on the basis of European Medicines Agency (EMA) guid-
ance, an immediate-release oral formulation of a generic copy (including nonsteroidal 
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anti-inflammatory drugs) might be approved as a biowaiver, 
by means of in vitro dissolution tests, without performing 
any clinical investigation.1 It is also being increasingly 
acknowledged that the regulatory criteria for assuming 
bioequivalence between branded and generic drugs might be 
insufficient at times, and this is an important issue deserving 
consideration, in order to ensure full therapeutic equiva-
lence in the postmarketing period. Therefore, performing 
postmarketing investigations on generic drugs appears to be 
important to control the quality of marketed formulations. Of 
note, some postmarketing studies are raising doubts on the 
actual therapeutic interchangeability between branded and 
generic drugs available in the pharmaceutical market. For 
instance, in a postmarketing pharmacokinetic (PK) cross-
over trial on two generic amoxicillin formulations, a lack 
of interchangeability was found for one generic product.2 
Moreover, some authors3–5 argued that switching from brand 
antiepileptics to generic copies might result in an increased 
risk of therapeutic failure (breakthrough seizures) or adverse 
reactions. Other examples of treatment failure, with mar-
keted antibiotic,6 anticoagulant,7 proton-pump inhibitor,8,9 
antiarrhythmic,10 or antidepressant11 generic products, have 
also been  published. Thus, the validity of current criteria for 
assessing interchangeability of generic and branded drugs is 
being questioned, at least in some instances, and it is becom-
ing evident that inadequate programs for postmarketing 
quality control of medicinal products might increase the risk 
of therapeutic failures and/or safety concerns in patients.12 
Moreover, generic drug use is steadily increasing in Italy, 
particularly in Tuscany, where the regional health authority 
strongly supports the prescription of such products in order 
to reduce health-care costs.
Based on the above considerations, our Clinical Pharma-
cology Centre for Drug Experimentation has implemented 
a research program to perform clinical studies aimed at 
verifying the quality of generic drugs available in the Italian 
pharmaceutical market, owing to specific scientific interest 
on the quality of generic drugs prescribed in current clinical 
practice.
Since nonsteroidal anti-inflammatory drugs represent 
one of the most prescribed pharmaceutical classes in 
Italy, we selected Mobic (Boehringer Ingelheim GmbH, 
 Ingelheim, Germany) as a branded meloxicam formulation 
and randomly selected Meloxicam Hexal among the generic 
compounds, both marketed in Italy, in order to evaluate 
whether the generic formulation fulfills the criteria for 
clinical PK bioequivalence versus its reference branded 
product.
The choice to indicate both the originator (Mobic) and 
generic (Meloxicam Hexal) meloxicam brand names was due 
to transparency reasons and the lack of any conflict of inter-
est between the respective drug companies and the authors. 
Moreover, we deemed it interesting to perform an explor-
atory pharmacodynamic (PD) study on the two meloxicam 
formulations, in order to assess their analgesic effects and 
compare their PD/PK relationship. In this regard, the PD test 
was carried out by estimating the mechanical pain threshold 
of cutaneous freeze injury with a von Frey device.13
Materials and methods
Subjects
Twenty-four healthy male volunteers were recruited at the 
Clinical Pharmacology Centre for Drug Experimentation 
of the University Hospital of Pisa (Italy). The exclusion of 
women from participating in the present study was due to sex-
dependent differences in the PK of meloxicam, as previously 
reported by Meineke and Türck,14 who demonstrated that both 
age and sex significantly affected meloxicam clearance.
In addition, this study investigated the relationship 
between the PK and PD of meloxicam in healthy volunteers, 
and therefore the exclusion of females was justified by the 
known hormonal influence on pain tolerance and threshold 
in menstruating women.15–18 At the same time, the exclusion 
of women might be regarded as a limitation, since a more 
heterogeneous study population might have increased the 
generalization of our findings. Eligible subjects were aged 
18–50 years, had a body mass index (BMI) between 19 and 
25 kg/m2, did not smoke, and had an unremarkable clinical 
history. Subjects with history or evidence of renal, gastroin-
testinal, hepatic, or hematologic abnormalities, any acute or 
chronic disease, or any drug allergy were excluded. Clinical 
evaluations and tests included: medical history, physical 
examination, height, weight, BMI, vital signs (heart rate, 
systolic and diastolic blood pressure, and body temperature), 
electrocardiogram, renal and liver-function tests, urinalysis, 
and urine drug and alcohol testing. Volunteers were requested 
to report any abnormality occurring throughout and after the 
study. Subjects were required to be negative for human immu-
nodeficiency virus (HIV) and hepatitis B and C viruses.
At the time of enrollment, the volunteers were informed 
of the purpose, duration, and risks of the study, and they 
were requested to sign a written informed consent. They 
were not allowed to consume alcohol, or beverages and 
foods containing caffeine from 48 hours prior to drug 
administration until the end of the study. All participants 
were requested to fast for 10 hours before drug dosing, in 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
304
Del Tacca et al
Therapeutics and Clinical Risk Management 2013:9
order to minimize the PK variability and allow appropri-
ate comparisons with data available in the literature.19–22 
The dietary regimen was the same for all subjects in both 
trial periods, and consisted of two standard meals served 
12 hours before and 5 hours and 9 hours after dosing. No 
additional food intake was allowed throughout the study 
period. Liquid consumption was allowed ad libitum from 
2 hours after dosing. Subjects were reimbursed for their time 
and transportation expenses, irrespective of whether they 
completed the study or not, in accordance with standard 
operating procedures implemented at our Clinical Phar-
macology Centre.23 The study was performed according to 
the rules of Good Clinical Practice24 and the Declaration of 
Helsinki;25 the study protocol was approved by the Ethics 
Committee of Pisa University Hospital.
Study design and drug administration
This was a single-dose, randomized, two-treatment, crossover, 
single-blind PK/PD evaluation designed to compare generic 
15 mg tablet Meloxicam Hexal (test product) with branded 
Mobic 15 mg tablets (reference product). The enrolled vol-
unteers were randomized into two groups of twelve subjects 
each, and each group received the two drug treatments at two 
different times, with an intervening 2-week washout period. 
Meloxicam tablets were administered with 250 mL of water 
at 8 am after overnight fasting. Venous blood samples of 5 mL 
were collected, through an indwelling cannula placed on the 
forearm, into Vacutainer™ (Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA) tubes (containing sodium heparin) 
at preset time intervals of 0 (predose), 0.5, 1, 2, 4, 6, 8, 12, 
and 24 hours after dosing. Blood samples were centrifuged 
at 900 g for 15 minutes; plasma samples were transferred 
into VacutainerTM tubes (no additive) and stored at −80°C 
until subsequent analysis.
Analytical method
Measurement of meloxicam concentrations in plasma 
samples was performed by validated high-performance 
liquid chromatography (HPLC) with ultraviolet detec-
tion,26 with some modifications. Briefly, for each sample, 
200 µL of plasma was added with 20 µL of piroxicam 
10 µg/mL (internal standard) plus 200 µL of acetonitrile 
acidified with H
3
PO
4
 0.1% (v/v), vortexed for 20 seconds, 
and centrifuged for 5 minutes at 11,000 rpm in a Heraeus 
Biofuge 15 (Thermo Fisher Scientific, Waltham, MA, USA) 
centrifuge. The clear supernatants (approximately 150 µL) 
were collected in vials and transferred into the autosampler. 
The Waters Breeze HPLC system (Waters, Milford, MA, 
USA), equipped with a Waters 2476 dual-wavelength ultra-
violet detector set at 355 nm, was used. The mobile phase, 
 consisting of potassium phosphate buffer (K
2
HPO
4
) 20 mM 
(pH 3.5) and acetonitrile (70:30, vol/vol), was isocratically 
pumped at a flow rate of 1.2 mL/minute through an Alltima 
CN chromatographic column, 150 × 4.6 mm, 5 µm (Alltech 
Italia, Milan, Italy). Plasma from untreated healthy subjects 
was used to reconstitute calibration and quality standards. In 
particular, for calibration standards, meloxicam was added to 
plasma to obtain final concentrations of 50, 10, 5, 2.5, 1.25, 
0.625, 0.313, 0.156, 0.078, and 0.039 mg/L in a final volume 
of 200 µL. Quality controls were prepared independently 
from calibration-standard samples at drug concentrations 
of 5, 0.625, and 0.078 mg/L. Samples were prepared and 
extracted as described above. Calibration curves of standard 
meloxicam were generated by plotting analyte peak areas 
versus drug concentrations, and linearity was estimated on 
at least three calibration curves obtained on 3 consecutive 
days. Calibration standards were also used to evaluate the 
parameters listed below.
Determination of meloxicam plasma 
concentration
Under the aforementioned chromatographic  conditions, 
meloxicam and piroxicam had retention times of 
5.93 minutes ± 0.03 minutes and 4.53 minutes ± 0.02 minutes, 
and their recovery accounted for 91% and 85%, respectively. 
The background noise (defined as the mean amplitude of 
baseline oscillations) was 5 µV, and the limit of detection – 
the concentration of analytes generating a signal three times 
higher than baseline noise – was estimated to be 0.005 mg/L 
on the basis of standard calibration curves. For meloxicam, 
the limit of quantification, defined as a sample concentration 
for which the method was still in the linear range, was equal 
to 0.039 mg/L, which represented the lowest concentration 
among the calibration standards. The linearity of calibra-
tion curves ranged between 0.039 mg/L and 5 mg/L, with a 
mean value of correlation coefficient for meloxicam equal 
to 0.989 ± 0.003. The linear range was calculated by means 
of linear regression analysis, obtaining a standard deviation 
of the residuals that accounted for 0.11 mg/L ± 0.09 mg/L. 
Precision and accuracy values were calculated as reported in 
a previous study.27 In particular, accuracy values accounted 
for 88.03%–114.66% over the whole range of the calibra-
tion standard. Precision values ranged from 2.01% up to 
7.00% over the entire range, with the exception of the lowest 
calibration standard (0.039 mg/L), the precision of which 
accounted for 17.90%. For quality controls, accuracy and 
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precision values were in the ranges of 87.00%–102.64% and 
2.98%–13.38%, respectively.
Pharmacokinetic evaluations
The actual times of sample collection were used for PK 
analysis of branded and generic meloxicam formulations. Area 
under the curve (AUC) from time 0 to 24 hours (AUC
0–24
) and 
AUC from time 0 to 5 hours (AUC
0–5
) were estimated by the 
linear trapezoidal method, while AUC from time 0 to infinity 
(AUC
0–inf
) was obtained by adding to the AUC
0–24
 value the 
C
24
/k
el
 ratio value, where C
24
 and k
el
 represent the plasma con-
centration of meloxicam at 24 hours postdose and the elimina-
tion constant, respectively. Maximum concentration (C
max
) and 
the time to achieve C
max
 (T
max
) were obtained from direct visual 
inspection of plasma concentration versus time curves.
PK parameters were calculated by a noncompartmental 
method using Stata version 10.0 (StataCorp, College Station, 
TX, USA). Bioequivalence comparison was carried out by 
the statistical software SAS version 8.2 (SAS Institute, Cary, 
NC, USA).
Pharmacodynamic evaluation
Twenty-two hours before the first day of each experimental 
session, a small skin area (designed as Z1) on the anterior 
glabrous region of the forearm was superficially frozen. For 
this purpose, the tip (1.8 cm2) of a cylindrical copper bar, pre-
viously cooled to −28°C, was applied to induce a first-degree 
burn injury. Interindividual variability in the intensity of the 
hyperemic response was low and blisters were never observed, 
in agreement with previous results from Chassaing et al.13 
Subsequently, sensory testing (ie, the assessment of baseline 
values of the first session) was performed 22 hours after the 
induction of cold injury. In the present study, mechanical 
hyperalgesia, as defined in the Textbook of Pain,28 was assessed 
by punctate-evoked pain with a von Frey device, as previously 
validated by Chassaing et al.13 Briefly, the quantification of 
pain, both at baseline and after treatment with meloxicam, was 
obtained by application of punctate stimuli with a constant 
slope of increasing punctate pressure up to the subjective 
perception of hyperalgesia. Mechanical pain threshold (MPT) 
was defined as the lowest pressure that produced a sensation 
of pain. Each MPT value was averaged from five separate 
consecutive measurements at different points within the test 
areas. A normal skin area (designed as Z0) on the contralat-
eral arm was used as control. Both basal and postdosing tests 
were performed by the same investigator, who was blind to 
drug allocation. The punctate stimulation was started well 
outside the hyperalgesic area, where no sensation of pain 
was experienced, and continued centripetally in 5 mm steps 
towards the site of freeze injury until the volunteer reported 
a subjective perception of hyperalgesia.
Statistical analysis
Randomization was performed using a random-number 
table. The groups were designated as RT (subjects who 
received first the reference and then the test product) 
and TR (subjects who received first the test and then the 
reference product). Analysis of variance (ANOVA) for a 
standard 2 × 2 crossover design was used to evaluate period, 
sequence, and formulation effect. Statistical analysis was 
performed by parametric mixed-model accounting for 
subjects included in nested sequences as random effect. 
Log-natural transformed AUC
0–24
 and C
max
 were used to 
evaluate the ratio and 90% confidence interval (CI) of 
the test drug over the reference product, according to 
Schuirmann’s procedure.29 Furthermore, T
max
 difference 
between the two meloxicam formulations was assessed by 
Mann–Whitney U test. Finally, demographic characteristics 
differences between the RT and TR groups were tested by 
one-way ANOVA or Mann–Whitney U test, according to 
the distribution of the variables of interest. PD subanalysis 
was performed by ANOVA for a standard 2 × 2 crossover 
design.
Tolerability assessment
Subjects were under continuous medical supervision at the 
study site throughout the study period. A physician, who was 
blind to the study treatment, was present throughout the study 
period to monitor the subjects and record possible adverse 
events (AEs). Every 2 hours, subjects were asked about and 
encouraged to report any unusual symptoms. Tolerability 
was assessed by investigators based on subject interviews, 
spontaneous reporting, vital signs, physical examination, 
and clinical laboratory tests (urinalysis, hematology, and 
blood chemistry) before and throughout the study period. 
Resting blood pressure, heart rate, and body temperature 
were monitored by investigators before drug administra-
tion (baseline) and every 2 hours throughout the study. 
AEs were considered serious if they were life-threatening 
or led to death, disability, inpatient hospitalization, or 
medical intervention to prevent permanent impairment or 
damage. All AEs were recorded on case-report forms by an 
 investigator. Any serious AE suspected to be drug-related 
by investigators was reported to the ethics committee and 
to the local pharmacovigilance authority in accordance with 
the study protocol.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
306
Del Tacca et al
Therapeutics and Clinical Risk Management 2013:9
Results
Subject characteristics
The baseline demographic characteristics of the two healthy 
volunteer groups are reported in Table 1. No differences 
between the RT and TR groups in terms of age, height, 
weight and BMI, systolic and diastolic blood pressure, or 
heart rate were found, indicating the substantial homogeneity 
of the two study groups.
Table 1 Summary of baseline demographic characteristics in the 
study population of healthy male volunteers
Demographic  
characteristics
RT group  
(n = 12)
TR group 
(n = 12)
Overall study  
population  
(n = 24)
P*
Age, years 27.1 (3.8) 25.5 (4.5) 26.3 (4.1) 0.415
Height, m 1.76 (0.07) 1.81 (0.10) 1.79 (0.08) 0.187
Weight, kg 74.6 (7.8) 75.9 (11.1) 75.2 (9.3) 0.738
BMI, kg/m2 24.0 (1.9) 23.1 (1.9) 23.6 (1.9) 0.260
SBP, mmHg 128.4 (8.3) 128.8 (9.1) 128.6 (8.5) 0.926
DBP, mmHg 73.3 (6.0) 77.0 (7.2) 75.2 (6.7) 0.188
Heart rate,  
beats/minute
66.9 (12.7) 76.5 (12.8) 71.7 (13.4) 0.080
Notes: Values are given as mean (standard deviation). *RT versus TR. Subjects in 
the RT group received first the reference formulation (Mobic) and then the test 
formulation (Meloxicam Hexal). Subjects in the TR group received first the test 
formulation (Meloxicam Hexal) and then the reference formulation (Mobic).
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure.
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Figure 1 Mean concentration–time profiles in plasma following the oral administration of 15 mg tablets of branded Mobic (•) or generic Meloxicam Hexal () formulation 
to healthy volunteers. Each point represents the geometric mean (95% confidence interval in vertical lines).
Pharmacokinetic evaluations
Mean plasma profiles of meloxicam in the study subjects, 
exposed to branded (Mobic) or generic (Meloxicam Hexal) 
formulations, are shown in Figure 1. The respective  values 
of estimated PK parameters are reported in Tables 2 
and 3.
Pharmacokinetic bioequivalence 
assessment
All the enrolled volunteers completed the study and were 
included in the final study population in order to perform 
statistical analysis. A significant period effect was found 
for AUC
0–24
 (P = 0.03) but not C
max
 (P = 0.09), with no 
sequence effect for either AUC
0–24
 or C
max
 (P = 0.7113 
and 0.8560, respectively), indicating a lack of formulation 
effect.  Moreover, coefficient of variation values, estimated 
by ANOVA, were slightly above the recommended upper 
limit of 30% (34% for AUC
0–24
 and 33% for C
max
).
When comparing the generic formulation of meloxicam 
with the respective branded product, the test/reference 
ratios and 90% CIs were 0.99 (0.84–1.16) for AUC
0–24
, 
0.98 (0.81–1.19) for AUC
0–inf
, and 1.05 (0.89–1.23) for C
max
. 
Moreover, no significant difference between the two meloxi-
cam formulations was found with regard to T
max
 (P = 0.472). 
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Discussion
Concerns are being raised about the possibility that the 
quality of some marketed generic drugs may not fully reflect 
the results obtained in preregistration bioequivalence inves-
tigations.30–32 Substitution of branded products with generic 
drugs is a matter of discussion, and it is often regarded with 
skepticism by both health-care providers and patients. Cur-
rent bioequivalence requirements are based on a measure 
of average bioequivalence; however, there are concerns that 
the use of such a measure might be inappropriate in the case 
of drugs with high intrasubject or intersubject variability, 
like analgesic medications.33 Moreover, in some countries, 
the lack of open access to documentation of preregistration 
studies represents a point of weakness of the generic drug 
market. Indeed, prescribing physicians cannot access any 
information on the preregistration development of generic 
drugs, and they can only trust that the regulatory authority 
approved a specific generic formulation in full accordance 
with recommended procedures. If a generic drug was 
Table 3 Values of the ratios of AUC0–5, AUC0–24, AUC0–inf, and 
Cmax with 90% confidence intervals
 Meloxicam Hexal/Mobic
AUC0–5 (mg × h/L) 1.09 (0.92–1.30)
AUC0–24 (mg × h/L) 0.99 (0.84–1.16)
AUC0–inf (mg × h/L) 0.98 (0.81–1.19)
Cmax (mg/L) 1.05 (0.89–1.23)
Abbreviations: AUC, area under the time–concentration curve; Cmax, maximum 
plasma concentration; h, hours;
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Figure 2 Mechanical pain threshold (MPT) at 5 hours determined by a von Frey 
device over the two sessions on control (Z0) and hyperalgesic (Z1) skin zone. Each 
session was performed according to the crossover study design (period 1 and period 2). 
Data are expressed as means ± standard deviation (vertical lines).
Table 2 Values of plasma pharmacokinetic parameters obtained from the study population of healthy male volunteers (n = 24) 
following the administration of generic (Meloxicam Hexal) and branded (Mobic) meloxicam formulations
Meloxicam Hexal Mobic
AUC(0–5) (mg × h/L)* 4.73 ± 0.42 4.29 (3.56–5.17) 4.29 ± 0.34 3.93 (3.31–4.68)
AUC(0–24) (mg × h/L)* 18.52 ± 1.65 16.97 (14.12–20.40) 18.49 ± 1.38 17.22 (14.55–20.39)
AUC(0–inf) (mg × h/L)* 31.44 ± 4.47 28.11 (22.06–35.81) 33.25 ± 4.03 27.85 (21.85–35.48)
Cmax (mg/L)* 1.32 ± 0.01 1.25 (1.07–1.45) 1.25 ± 0.09 1.18 (1.01–1.38)
Tmax (h)
† 5.21 ± 0.59 4.00 (1.00–12.00) 5.75 ± 0.53 5.00 (4.00–12.00)
t½
† 30.61 ± 5.35 17.83 (5.23–90.04) 38.05 ± 9.90 22.68 (6.12–233.51)
Notes: *Data are reported as both arithmetic mean ± standard error, and geometric mean with 95% confidence interval; †data are reported as both arithmetic mean ± 
standard error and median with 2.5 and 97.5 percentiles.
Abbreviations: AUC, area under the time–concentration curve; Cmax, maximum plasma concentration; Tmax, time to Cmax; t½, half-life; h, hours;
Thus, on the basis of EMA guidelines, the 90% CI for 
the relevant PK parameters fell within the acceptability range 
of 0.80–1.25, indicating pharmacokinetic bioequivalence 
between the two meloxicam products. Bioequivalence was 
not confirmed when AUC
0–5
 test/reference ratio with CI was 
calculated: the ratio was 1.09 and CI 0.92–1.30 (Table 3).
Pharmacodynamic evaluation
A significant difference of MPT values between control (Z0) 
and hyperalgesic skin areas (Z1) was observed (74.8 ± 8.7 
versus 58.2 ± 7.4, P , 0.001). The MPT values for each area 
(Z0, Z1) at 5 hours are displayed in Figure 2. The mean MPT 
values presented a period effect, with a reduction of both Z0 
and Z1 MPT in the second period of the study. No significant 
differences between the two formulations of meloxicam were 
found: 63.7% ± 22.5% versus 52.3% ± 13.0% at baseline 
(P = 0.940) and 88.2% ± 34.5% versus 57.8% ± 17.5% 
at 5 hours (P = 0.797) for Mobic and Meloxicam Hexal, 
respectively.
Tolerability
Two not-serious AEs were recorded during the study. A skin rash 
with headache developed in a volunteer 30 minutes after Mobic 
administration, with a spontaneous recovery after 2 hours; this 
AE was considered as probably related to the investigational 
medicinal product administration. One subject reported cervical 
pain, which was considered as drug-unrelated.
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approved with only the minimum of regulatory requirements 
for its registration (ie, by an in vitro study), the postmarket-
ing interchangeability of that generic drug with its respective 
branded product might not be warranted. Based on these con-
siderations, the present study was performed: (1) to compare 
the PK profiles of two meloxicam formulations (branded and 
generic), containing different excipient ingredients, in order 
to verify whether the generic formulation conforms with its 
respective branded product, in accordance with the criteria 
established by EMA guidelines and Italian laws; and (2) to 
evaluate whether a PD end point comparison can be related 
to PK analysis and is suitable for improving the control of 
quality pursued by postmarketing studies.
In accordance with EMA guidelines, estimated PK 
parameters AUC
0–24
 and C
max
 fell within the acceptability 
range of 0.80–1.25, indicating the interchangeability between 
the two meloxicam products and confirming that PK analysis 
is consistent with PD comparison results. Bioequivalence 
was not confirmed in a subanalysis of AUC
0–5
 due to the 
huge variation of standard deviation in the first phases of PK 
(dissolution/absorption), but PD testing at 5 hours showed 
that there was no difference between formulations in terms 
of drug effects.
It is worth noting that the AUC
0–5
 PK end point is not con-
sidered by current guidelines, but the present study focused 
attention on this end point to investigate whether it could 
predict the analgesic effect early after drug administration. 
Moreover, the PD test was considered an explorative analysis, 
and taking into account the huge variation obtained in this 
analysis, the PD results led to a more probable beta error, thus 
making arguable the acceptance of the null hypothesis (drug 
equivalence). Since large intersubject variability of AUC
0–5
 
values and PD results hampered our analysis, this issue should 
be carefully considered in future studies, where the collection 
of plasma samples at earlier time points would allow more 
reliability and confidence in the results to be obtained.
The time-point collection (24 hours), which was not 
long enough to cover two drug half-lives, could appear as 
a limitation of the present study. However, the main study 
objective was not to investigate the complete PK profiles of 
meloxicam in healthy volunteers, since this information has 
been previously provided by other authors,19–22,34,35 but rather 
to compare PK and PD patterns between branded and generic 
meloxicam. On this basis, we performed a blood-sampling 
collection during the dissolution, absorption, and distribution 
PK phases, assuming that the elimination phase would not 
be significantly affected by the pharmaceutical formulation. 
Consistently with this assumption, when the present PK 
results were compared with those published earlier,36 the 
length of time sampling appeared to be long enough to allow 
a good estimation of meloxicam PK.
The present results are in agreement with previous 
PK data19–22,34 obtained on branded meloxicam in healthy 
volunteers. When considering the study performed by Marcelín-
Jiménez et al35 in a Mexican female population, although 
the T
max
 value was similar to that estimated in the present 
study, both C
max
 and AUC
0–24
 values were found to be higher. 
However, differences in sex, body weight, genetic profile, and 
pharmaceutical composition of tablets are likely to explain the 
differences between the Italian and Mexican studies.
If two drugs are proven to be interchangeable, high-
quality manufacturing standards are followed, and stringent 
quality controls are ensured over time, then the switch from 
a brand formulation to a generic one should be acceptable 
in most cases, without any expected noticeable variation in 
efficacy or tolerability.37 However, postmarketing evaluations 
have highlighted cases of lack of equivalence between generic 
and branded drugs. One case is the study by Del Tacca et al,2 
who compared brand amoxicillin with two generic formu-
lations available in the Italian market, and did not confirm 
interchangeability for one of the two generic products. In 
another study, the lack of postmarketing therapeutic equiva-
lence between branded and generic cefuroxime was found to 
significantly influence the incidence of postoperative infec-
tions in adult patients undergoing coronary artery bypass 
grafting surgery.6 Development of breakthrough seizures 
and increased seizure frequency was observed after switch-
ing to marketed generic antiepileptic drugs, possibly due 
to changes in serum concentrations.4 Likewise, psychiatric 
symptom relapse in a stabilized patient, resulting in hospi-
talization, after a switch to a marketed generic formulation 
of clozapine,38 has been reported. In the postmarketing set-
ting, plasma levels of venlafaxine and its active metabolite 
O-desmethylvenlafaxine were found to be significantly higher 
in subjects given a generic product, as compared with those 
treated with the branded formulation.11
Overall, bioequivalence studies should be considered 
not only as a part of the regulatory process, which allows 
the marketing authorization of a generic drug, but also 
as valuable scientific tools suitable for evaluating the 
“goodness” (ie, the quality) of generic drugs available in the 
pharmaceutical market, thus reducing the risks associated 
with a lack of interchangeability persistence. In particular, 
by means of comparative bioequivalence studies between 
generic products and their respective branded drugs in the 
postmarketing setting, we could assure for both patients and 
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prescribing physicians not only a pharmaceutical but also 
a pharmacological (ie, PK and/or PD) equivalence, which 
would add support to the expected clinical efficacy of the 
marketed generic drug. Accordingly, an efficient program of 
postmarketing drug evaluation should take into account PK, 
and in some (specific) cases PD studies with single or multiple 
doses (when reaching a steady-state level is deemed relevant). 
In this respect, the present study suggests that PD evaluations 
may represent simple and useful tools, which might improve 
the quality of postmarketing comparisons. Indeed, when the 
PD equivalence analysis of generic and branded formula-
tions completes the PK evaluation, the existence of actual 
interchangeability can be better documented.
Conclusion
The results of the present postmarketing study demon-
strate that the PK profiles of the branded and generic 
meloxicam  formulations confirm the regulatory criteria for 
 bioequivalence. Taken together with the PD data, these results 
indicate that both formulations can be used interchangeably 
in clinical practice.
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